Pàgina inicial > Resultats de la cerca: Munir, T.
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 4 registres trobats en 1.24 segons.
Articles, 4 registres trobats
Articles 4 registres trobats  
1.
17 p, 1.2 MB Impact of Minimal Residual Disease on Progression-Free Survival Outcomes after Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study / Munir, Talha (St James's Hospital) ; Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Owen, Carolyn (Tom Baker Cancer Centre) ; Follows, George (Addenbrookes Hospital (Cambridge, Regne Unit)) ; Benjamini, Ohad (Sheba Medical Center) ; Janssens, Ann (UZ Leuven Gasthuisberg) ; Levin, Mark-David (Albert Schweitzer Hospital) ; Osterborg, Anders (Karolinska University Hospital and Karolinska Institutet (Suecia)) ; Robak, Tadeusz (Medical University of Lodz. Copernicus Memorial Hospital) ; Simkovic, Martin (University Hospital Hradec Kralove (República Txeca)) ; Stevens, Don (Norton Cancer Institute) ; Voloshin, Sergey (Russian Scientific and Research Institute of Hematology and Transfusiology) ; Vorobyev, Vladimir (S.P. Botkin Moscow City Clinical Hospital) ; Yagci, Munci (Gazi Universitesi Tip Fakultesi) ; Ysebaert, Loic (Institut Universitaire du Cancer Toulouse Oncopole) ; Qi, Keqin (Janssen Research & Development) ; Qi, Qianya (Janssen Research & Development) ; Parisi, Lori (Janssen Research & Development) ; Srinivasan, Srinivasan (Oncology Translational Research. Janssen Research & Development) ; Schuier, Natasha (Janssen Research & Development) ; Baeten, Kurt (Janssen Research & Development) ; Howes, Angela (Janssen Research & Development) ; Caces, Donne Bennett (Janssen Research & Development) ; Niemann, Carsten U (Rigshospitalet Copenhagen University Hospital) ; Kater, Arnon P. (Amsterdam Medical Centers. University of Amsterdam)
PURPOSEIn GLOW, fixed-duration ibrutinib + venetoclax showed superior progression-free survival (PFS) versus chlorambucil + obinutuzumab in older/comorbid patients with previously untreated chronic lymphocytic leukemia (CLL). [...]
2023 - 10.1200/JCO.22.02283
Journal of Clinical Oncology, Vol. 41 Núm. 21 (20 2023) , p. 3689-3699  
Registre complet - Creative Commons
2.
9 p, 500.3 KB Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL / Brown, J.R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Hillmen, Peter (St James Institute of Oncology) ; O'Brien, S. (MD Anderson Cancer Center) ; Barrientos, J.C. (Hofstra Northwell School of Medicine) ; Reddy, N.M. (Vanderbilt-Ingram Cancer Center) ; Coutre, S.E. (Stanford University) ; Tam, Constantine S (Peter MacCallum Cancer Centre. St Vincent's Hospital) ; Mulligan, S.P. (Royal North Shore Hospital) ; Jaeger, U. (Medical University of Vienna) ; Barr, P.M. (University of Rochester Cancer Center) ; Furman, R.R. (New York Presbyterian Hospital) ; Kipps, Thomas J (UCSD Moores Cancer Center) ; Cymbalista, F. (Hôpital Avicenne) ; Thornton, P. (Beaumont Hospital (Dublín, Irlanda)) ; Caligaris-Cappio, F. (Universita Vita-Salute San Raffaele) ; Delgado, J. (Hospital Clínic i Provincial de Barcelona) ; Montillo, M. (Niguarda Hospital) ; DeVos, S. (David Geffen School of Medicine at UCLA) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Pagel, J.M. (Swedish Cancer Institute) ; Munir, Talha (St James Institute of Oncology) ; Burger, Jan A (MD Anderson Cancer Center) ; Chung, D. (Pharmacyclics LLC. AbbVie Company) ; Lin, J. (Pharmacyclics LLC. AbbVie Company) ; Gau, L. (Pharmacyclics LLC. AbbVie Company) ; Chang, B. (Pharmacyclics LLC. AbbVie Company) ; Cole, G. (Pharmacyclics LLC. AbbVie Company) ; Hsu, E. (Pharmacyclics LLC. AbbVie Company) ; James, D.F. (Pharmacyclics LLC. AbbVie Company) ; Byrd, J.C. (Ohio State University) ; Universitat Autònoma de Barcelona
In the phase 3 RESONATE study, ibrutinib demonstrated superior progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) compared with ofatumumab in relapsed/refractory CLL patients with high-risk prognostic factors. [...]
2018 - 10.1038/leu.2017.175
Leukemia, Vol. 32 Núm. 1 (january 2018) , p. 83-91  
Registre complet - Creative Commons
3.
13 p, 1.9 MB Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features : integrated analysis of two phase 3 studies / Burger, Jan A (Department of Leukemia. University of Texas MD Anderson Cancer Center) ; Robak, Tadeusz (Medical University of Lodz. Copernicus Memorial Hospital) ; Demirkan, Fatih (Dokuz Eylul University) ; Bairey, Osnat (Rabin Medical Center) ; Moreno, Carolina (Institut d'Investigació Biomèdica Sant Pau) ; Simpson, D. (BeiGene) ; Munir, Talha (Department of Haematology. St. James's Hospital) ; Stevens, D.A. (Norton Cancer Institute) ; Dai, S. (Pharmacyclics LLC. an AbbVie Company) ; Cheung, Leo W. K (Pharmacyclics LLC. an AbbVie Company) ; Kwei, Kevin (Pharmacyclics LLC. an AbbVie Company) ; Lal, Indu (Pharmacyclics LLC. an AbbVie Company) ; Hsu, E. (Pharmacyclics LLC. an AbbVie Company) ; Kipps, Thomas J (University of California San Diego. Moores Cancer Center) ; Tedeschi, A. (ASST Grande Ospedale Metropolitano Niguarda)
Genomic abnormalities, including del(17p)/TP53 mutation, del(11q), unmutated IGHV, and mutations in BIRC3, NOTCH1, SF3B1, and XPO1 predict poor outcomes with chemoimmunotherapy in chronic lymphocytic leukemia. [...]
2022 - 10.1080/10428194.2021.2020779
Leukemia and Lymphoma, Vol. 63 Núm. 6 (2022) , p. 1375-1386  
Registre complet - Creative Commons
4.
11 p, 1.8 MB Final analysis from RESONATE : Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma / Munir, Talha (St. James's Hospital ( Dublín, Irlanda)) ; Brown, J. R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; O'Brien, Susan (UC Irvine. Chao Family Comprehensive Cancer Center) ; Barrientos, Jacqueline C. (Northwell Health Cancer Institute (Estats Units d'Amèrica)) ; Barr, Paul M (Wilmot Cancer Institute. University of Rochester Medical Center) ; Reddy, N. M. (Vanderbilt-Ingram Cancer Center) ; Coutre, Steven E. (Stanford Cancer Center. Stanford University School of Medicine) ; Tam, C. S. (Peter MacCallum Cancer Centre. St. Vincent's Hospital and University of Melbourne) ; Mulligan, S. P. (Royal North Shore Hospital) ; Jaeger, Ulrich (Division of Hematology and Hemostaseology. Medical University of Vienna) ; Kipps, T. J. (UCSD Moores Cancer Center) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Montillo, M. (Niguarda Ca' Granda Hospital) ; Burger, Jan A (Department of Leukemia. University of Texas MD Anderson Cancer Center) ; Byrd, J. C. (The Ohio State University Comprehensive Cancer Center) ; Hillmen, Peter (The Leeds Teaching Hospitals. St. James Institute of Oncology) ; Dai, Sandra (Pharmacyclics LLC. an AbbVie Company) ; Szoke, A. (Pharmacyclics LLC. an AbbVie Company) ; Dean, James P. (Pharmacyclics LLC. an AbbVie Company) ; Woyach, J. A. (The Ohio State University Comprehensive Cancer Center) ; Universitat Autònoma de Barcelona
Ibrutinib, a once-daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). [...]
2019 - 10.1002/ajh.25638
American Journal of Hematology, Vol. 94 Núm. 12 (january 2019) , p. 1353-1363  
Registre complet - Creative Commons

Vegeu també: autors amb noms similars
5 Munir, Talha
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem